therapeutics_3

ADCs for ES-SCLC. Image credit: DOI: 10.3390/genes15060701Extensive-stage small-cell lung cancer (ES-SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Antibody drugs, especially immune checkpoint inhibitors, have emerged as a promising treatme

Antibody therapeutics revolutionize oncology. Biointron highlights checkpoint inhibitors, targeted antibodies, and strategies advancing cancer treatment.

Learn how vaccines trigger antibody production, the immune mechanisms behind protection, different vaccine types, and key factors influencing efficacy and long-term immunity.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

Muronomab (Orthoclone OKT3) made history as the first FDA-approved monoclonal antibody. Biointron reviews its impact on immunotherapy and antibody drug development.

Discover highlights from Biointron’s Lunch & Learn with MassBio, featuring HTP antibody platforms, alpaca VHH discovery, bispecific antibodies, and ADC development.

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.

Explore the role of anti-idiotype antibodies and critical reagents in therapeutic antibody development, ensuring specificity, potency, and safety in drug testing.

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Learn about Fab, F(ab')2, and Fc antibody fragments—how they are generated, their roles in antigen targeting, and their evolving applications in biomedical research and therapy.

The development and approval of novel antibody drugs represent a significant segment of pharmaceutical innovation, addressing a wide range of diseases from cancer to autoimmune disorders. Since the first monoclonal antibody (mAb) drug was approved in 1986, there has been explosive growth in this area. By 2021, the US FDA had approved its 100th mAb product, with mAbs now accounting for nearly a fifth of the agency’s new drug approvals each year.

Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.

This week, exciting news came out that Eledon Pharmaceuticals’ tegoprubart was successfully used to aid the first-ever transplant of a genetically-edited pig kidney into a 62-year-old man with end-stage kidney disease. Tegoprubart is an investigational anti-CD40L antibody that has a high affinity for CD40 ligand. CD40L signaling plays an important role in adaptive and innate immune cell activation and function, and is therefore a target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.